leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto German partner 3a Diagnostics planning to develop two saliva tests for Coronavirus

XPhyto (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to bring news their exclusive diagnostic partner, 3a-Diagnostics is developing a reverse transcription-polymerase chain reaction kit targeting COVID-19 with results in 25 minutes.

Rogers telling Proactive they are planning two test kits and they expect to launch them in the European market in Q-1 2021.

Quick facts: XPhyto Therapeutics Corp.

Price: 2.23 CAD

CSE:XPHY
Market: CSE
Market Cap: $129.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics continues to move toward commercialization of their...

XPhyto Therapeutics (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide an update on their plans to go to market in Europe with their testing program for the COVID-19 Rogers talks about where that program is AT and also about their drug delivery platform...

3 weeks, 3 days ago

2 min read